Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 192 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014', provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Refractory Chronic Lymphocytic Leukemia (CLL) Overview 10
Therapeutics Development 11
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 11
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 12
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 13
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 16
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 20
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 21
Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
Boehringer Ingelheim GmbH 23
F. Hoffmann-La Roche Ltd. 24
Sanofi 25
AstraZeneca PLC 26
GlaxoSmithKline plc 27
MedImmune, LLC 28
Infinity Pharmaceuticals, Inc. 29
Piramal Enterprises Limited 30
Novartis AG 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
Celgene Corporation 34
Immunomedics, Inc. 35
TG Therapeutics, Inc. 36
Pharmacyclics, Inc. 37
MorphoSys AG 38
Threshold Pharmaceuticals, Inc. 39
Onconova Therapeutics, Inc. 40
LFB S.A. 41
Advancell 42
Rhizen Pharmaceuticals SA 43
AbbVie Inc. 44
SpectraMab GmbH 45
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
ibrutinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
duvelisib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
venetoclax - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
venetoclax + rituximab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
vismodegib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
acadesine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AT-7519 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MOR-208 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MEDI-551 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
tisagenlecleucel-T - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
afuresertib hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cell Therapy to Target CD20 for Chemotherapy Resistant Cancers - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Cell Therapy to Target CD19 for Oncology - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
moxetumomab pasudotox - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
trametinib dimethyl sulfoxide - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
FBTA-05 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PRT-2070 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cell Therapy for Leukemia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
obinutuzumab - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
SAR-245408 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TH-302 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
rigosertib sodium - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
ulocuplumab - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
IMMU-114 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ublituximab - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
spebrutinib besylate - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
BI-836826 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
P-2745 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
BMS-986016 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
TGR-1202 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
TG-1101 + TGR-1202 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
AZD-6738 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
ACP-196 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
venetoclax + obinutuzumab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
UC-961 - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
AGS-67E - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Cell Therapy for B-Cell Lymphomas - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Triplebody 19x16x19 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Small Molecules to Inhibit MDM2 for Oncology - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 132
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 181
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 182
Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 183
Featured News & Press Releases 183
Jun 27, 2014: GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL 183
May 31, 2014: AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting 183
Apr 30, 2014: First Quarter 2014 Net Sales Figures for Arzerra 184
Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 184
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 185
Oct 22, 2013: MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208 185
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 186
Jun 19, 2013: Janssen Announces Publication Of Phase Ib/II Trial Data Of Ibrutinib In Relapsed Or Refractory Chronic Lymphocytic Leukemia In The New England Journal Of Medicine 187
Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting 188
May 15, 2013: Onyx Pharma To Present Data On Kyprolis At 49th American Society Of Clinical Oncology Annual Meeting 190
Appendix 191
Methodology 191
Coverage 191
Secondary Research 191
Primary Research 191
Expert Panel Validation 191
Contact Us 192
Disclaimer 192

List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2014 11
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 21
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2014 22
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 23
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 24
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2014 25
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca PLC, H2 2014 26
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline plc, H2 2014 27
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2014 28
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 29
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Piramal Enterprises Limited, H2 2014 30
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2014 31
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2014 32
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 33
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2014 34
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2014 35
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2014 36
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H2 2014 37
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2014 38
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 39
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onconova Therapeutics, Inc., H2 2014 40
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2014 41
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Advancell, H2 2014 42
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 43
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2014 44
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by SpectraMab GmbH, H2 2014 45
Assessment by Monotherapy Products, H2 2014 46
Assessment by Combination Products, H2 2014 47
Number of Products by Stage and Target, H2 2014 50
Number of Products by Stage and Mechanism of Action, H2 2014 53
Number of Products by Stage and Route of Administration, H2 2014 55
Number of Products by Stage and Molecule Type, H2 2014 57
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2014 132
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2014 181
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2014 182